The expanded indication makes lenalidomide the first and only treatment to receive FDA approval for maintenance use following autologous hematopoietic stem cell transplant.
来那度胺适应症扩展后，成为FDA批准的第一个也是唯一的用于自体造血干细胞移植后维持治疗的药物。
The expanded indication makes lenalidomide the first and only treatment to receive FDA approval for maintenance use following autologous hematopoietic stem cell transplant.
来那度胺适应症扩展后，成为FDA批准的第一个也是唯一的用于自体造血干细胞移植后维持治疗的药物。
应用推荐